Particle therapy for prostate cancer: The past, present and future

Hitoshi Ishikawa, Hiroshi Tsuji, Shigeuki Murayama, Mikio Sugimoto, Nobuo Shinohara, Satoru Maruyama, Motohiro Murakami, Hiroki Shirato and Hideyuki Sakurai

1Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, 2Hospital of the National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, 3Division of Proton Therapy, Shizuoka Cancer Center Hospital, Shizuoka, 4Department of Urology, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, 5Department of Urology, Hokkaido University Graduate School of Medicine, and 6Global Station for Quantum Medical Science and Engineering, Global Institution for Collaborative Research and Education, Hokkaido University, Sapporo, Hokkaido, Japan

Abstract: Although prostate cancer control using radiotherapy is dose-dependent, dose-volume effects on late toxicities in organs at risk, such as the rectum and bladder, have been observed. Both protons and carbon ions offer advantageous physical properties for radiotherapy, and create favorable dose distributions using fewer portals compared with photon-based radiotherapy. Thus, particle beam therapy using protons and carbon ions theoretically seems suitable for dose escalation and reduced risk of toxicity. However, it is difficult to evaluate the superiority of particle beam radiotherapy over photon beam radiotherapy for prostate cancer, as no clinical trials have directly compared the outcomes between the two types of therapy due to the limited number of facilities using particle beam therapy. The Japanese Society for Radiation Oncology organized a joint effort among research groups to establish standardized treatment policies and indications for particle beam therapy according to disease, and multicenter prospective studies have been planned for several common cancers. Clinical trials of proton beam therapy for intermediate-risk prostate cancer and carbon-ion therapy for high-risk prostate cancer have already begun. As particle beam therapy for prostate cancer is covered by the Japanese national health insurance system as of April 2018, and the number of facilities practicing particle beam therapy has increased recently, the number of prostate cancer patients treated with particle beam therapy in Japan is expected to increase drastically. Here, we review the results from studies of particle beam therapy for prostate cancer and discuss future developments in this field.

Key words: biochemical relapse-free survival, carbon-ion radiotherapy, prostate cancer, proton beam therapy, toxicity.

Background of external beam RT for prostate cancer

Approximately 165 000 people develop prostate cancer per year in the USA, with 29 000 prostate cancer-related deaths per year. In Japan, the annual number of newly diagnosed patients increases every year, and prostate cancer is currently the cause of death of >12 000 patients. As recent advances in prostate cancer screening and treatment have led to an improvement in patient outcomes, the treatment goals have changed from merely tumor control to preservation of the daily activities and QOL of patients as important end-points in comparisons of the various treatment options. In particular, it is important that treatment is as minimally invasive as possible for elderly patients.

According to recent large-scale comparative studies evaluating several end-points, such as prostate cancer-specific mortality rate, disease progression, metastasis and all-cause mortality rate, external beam RT produces outcomes comparable with those of surgery; RT has thus been established as a curative treatment for prostate cancer. Reports have shown that as the radiation dose used for prostate cancer is increased, a dose–response relationship is observed between the RT dose and tumor control. Conversely, increasing the RT dose leads to concerns about adverse events in the rectum and bladder, and decreasing the RT dose and...
volume in these organs decreases the incidence of adverse events, according to several studies that carried out dose–volume histogram analyses.6–8 Thus, if the RT dose to the prostate can be increased without increasing the irradiated volume in the rectum and bladder, treatment outcomes will improve.

With X-ray-based RT regimens, a dose build-up effect occurs 1–2 cm from the body surface. After delivery of the peak dose, the deeper the rays penetrate into the body, the more gradual the decrease in the relative dose as the rays pass through the body. In contrast, charged particle beams differ from photon beams in that they create a better dose distribution in the target volume by specific beam modulations, such as a SOBP (Fig. 1).9–11 Thus, the prescribed dose can be delivered to the lesion through a smaller number of beams with particle beam RT compared with photon beam RT, and consequently the irradiated volume and dose in the rectum and bladder in particle beam RT for prostate cancer can be decreased compared with photon beam RT, such as IMRT and volumetric-modulated arc therapy (Fig. 2).12 One reason why particle beam RT is useful for treating prostate cancer is that dose escalation using modern techniques has improved tumor control rates, especially bRF or bRFS rates, in photon beam RT series, and charged particles might be even more useful for safely escalating the RT dose.13–15

In this article, we review the results of previous particle beam RT studies compared with photon beam RT, and introduce ongoing studies and future prospects to establish high-quality evidence for particle beam RT for prostate cancer.

Scientific statements
Concomitant photon and proton beam RT: 1990s to early 2000s

The treatment outcomes of four randomized comparative trials carried out in the 1990s (two photon beam RT studies and two studies on combination of PBT with photon beam RT) and a PBT study carried out at Loma Linda University are shown in Table 1.5,16–19 At that time, the appropriate use of ADT combined with RT for prostate cancer was not yet established, and pelvic RT using photons was a standard treatment for latent lymph node involvement. PBT was therefore used as a RT boost to the prostate after pelvic RT. Shipley et al.14 reported the results from the first randomized PBT study carried out at Massachusetts General Hospital Cancer Center. In their study, patients in the standard-dose group were treated with pelvic RT at 50.4 Gy/28 fr, followed by local photon beam RT at 16.8 Gy/8 fr (total dose 67.2 Gy/36 fr), and those in the high-dose group were treated with PBT at 25.2 GyE/12 fr together with pelvic RT (total dose 75.6 GyE/40 fr). Good local control was achieved in the high-dose PBT group, in which the 8-year local control rate was 73% compared with 59% in the standard-dose photon beam RT group.14 Especially among the patients with poorly differentiated adenocarcinoma, the rate in the high-dose group was significantly better (84% vs 19%, P = 0.0014). Furthermore, grade 3 rectal bleeding was seen in just 2.9% of the patients in the high-dose group. In contrast, the Radiation Therapy Oncology Group carried out a randomized trial using photon beam RT (RTOG9413), designed as a 2 × 2 factorial study using ADT sequencing as one stratification factor and the radiation field as the other factor. In a secondary analysis, pelvic RT combined with neoadjuvant ADT was added for disease control of patients who had an estimated risk of lymph node involvement of >15%, according to the equation: percentages of positive lymph nodes = (2/3) PSA + [(GS − 6) × 10] or T2c–T4 diseases, and showed an improvement in PFS compared with prostate-only RT; however, despite using a 70.2 Gy dose (5.4 Gy lower than the aforementioned 75.6 Gy PBT dose), grade 3 GI toxicities were noted in 4.3% of patients15 (Table 1).

The effect of a high-dose PBT boost after local photon beam RT on the outcomes of patients with stage T1–2 prostate cancer was evaluated in the PROG95-09 trial.16 A PBT boost of either 19.8 GyE/11 fr (standard-dose group) or 28.8 GyE/16 fr (high-dose group) was delivered to the prostate at a total dose of 50.4 Gy/28 fr after conformal photon beam RT. After a median observation period of 8.9 years, the 10-year biochemical failure rates were 32.4% in the standard-dose group and 16.7% in the high-dose group (P < 0.0001), but grade 3 GI and GU events were only noted in 1% and 2% of patients in the high-dose group, respectively. At almost the same time, long-term results from a randomized dose-escalation trial of photon beam RT for prostate cancer carried out at the MD Anderson Cancer Center were reported.16 In that study, the treatment outcomes of the standard-dose (70 Gy/35 fr) group and high-dose (78 Gy/39 fr) group were compared (Table 1). The 10-year recurrence-free rate was 50% in the standard-dose group versus 73% in the high-dose group, showing that the higher dose produced better results (P = 0.004). However, grade 3 GI and GU adverse events were observed in 7% and 5% of patients, respectively, in the high-dose group, indicating higher adverse event rates compared with those induced by the 79.2 GyE dose of the high-dose group in the ROG95-09 trial described above (Table 1).
In Japan, to confirm the safety of localized PBT, phase II clinical studies were carried out at the National Cancer Center Hospital East, in which 30 patients were registered over 2 years starting in 2001. Photon beam RT consisting of 50 Gy/25 fr was delivered to the prostate and bilateral seminal vesicles, followed by a PBT boost of 26 GyE/13 fr to the prostate alone. No grade 3 acute or late toxicities were observed, confirming the feasibility of high-dose RT with a PBT boost for prostate cancer.18

Local particle beam RT: Mainly in the 2000s

At Loma Linda University, high-dose PBT without photons was used to treat localized prostate cancer. Between 1991 and 1997, 911 cases were treated with localized PBT at a total dose of 74–75 Gy, and a 5-year bRFS of 82% was reported. No grade 3 adverse events were noted, and grade 2 toxicities included 3.5% GI and 5.4% GU events. Thus, the use of PBT alone seemed superior to photon beam RT alone or photon beam RT combined with PBT17 (Table 1). In addition, the morbidity rates for prostate cancer have been evaluated based mainly on grade 2 GI and GU adverse events since then.

In Japan, three facilities – the National Cancer Center Hospital East, Shizuoka Cancer Center and Hyogo Ion Beam Medical Center – carried out a multicenter collaborative phase II clinical trial of local PBT, delivered at a total dose of 74 GyE/37 fr to 151 prostate cancer patients between March 2004 and March 2007. In that trial, no grade 3 adverse events occurred, and grade 2 late GI and GU toxicities were observed in 2.0% and 4.1% of patients, respectively.19 Heavy ion RT using carbon ions for prostate cancer has been carried out at the National Institutes of Radiological Sciences in Japan since 1995; the optimal RT dose and technique were established through two phase I/II dose-escalation studies of hypofractionated CIRT carried out there.20 In the phase II trial, which was carried out between April 2000 and October 2003, a 66 GyE/20 fr dose fractionation schedule was used based on recommendations from previous studies, which resulted in grade 2 GI and GU toxicities in 1.7% and 5.1% of patients, respectively.21

At the beginning of the 21st century, during which the above results were published, new radiation technologies,
such as IMRT and image-guided brachytherapy, became widely available as definitive RT modalities for prostate cancer. Furthermore, comparative studies and meta-analyses showed that ADT improved treatment outcomes, especially for intermediate- and high-risk prostate cancer, and the ideal duration and timing of concomitant ADT were determined. The treatment outcomes of local high-dose RT combined with ADT were equal to or superior to those of pelvic or prostate RT, combined with ADT were equal to or superior to those of pelvic or prostate RT, which has become the main treatment for prostate cancer without evidence of metastasis.

Table 2 summarizes the clinical outcomes after IMRT, PBT and CIRT, along with a comparison of the efficacies and safety parameters.8,25–38 PBT and CIRT outcomes in Japanese patients were reported recently in a multicenter collaborative clinical study.37,38 Iwata et al. reported long-term outcomes from a multi-institutional survey of PBT for prostate cancer carried out by the Japanese Radiation Oncology Study Group. In their study, 1291 patients at seven facilities received PBT between January 2008 and December 2011, mainly using the standard fractionation for RT at total doses ranging from 70 to 80 GyE. After a median follow-up period of 69 months (range 7–107 months), the 5-year bRFS rates of the low-, intermediate- and high-risk patients were 97.0%, 91.1% and 83.1%, respectively, and grade 2 GI and GU adverse events were observed in 4.1% and 4.0% of patients, respectively.37 In another study, the treatment outcomes of 2157 patients who received CIRT at three facilities between 2003 and 2014 were analyzed.38 Based on the results of clinical studies carried out at the National Institute of Radiological Sciences, dose fractionation schedules of CIRT have been changed from 20 sessions over 5 weeks to 12 sessions over 3 weeks step-by-step.8,21,39 After a median observation period of 29 months, the 5-year bRFS rates of the low-, intermediate- and high-risk patients were 92%, 89% and 92%, respectively, and the rates of grade 2 GI and GU adverse events were 0.4% and 4.6%, respectively.38 Furthermore, Okada et al.39 showed no significant difference in the 5-year biochemically relapse-free rates between 16 and 20 sessions groups (88.5% and 90.2%, respectively), and the decrease in the number of CIRT fractions did not increase the incidences of the late adverse events (Table 3).8,39,40 Thus, particle beam RT was shown to achieve well-balanced treatment outcomes in terms of both efficacy and safety.

### Comparisons of RT methods in terms of HRQOL

Recent advances in RT technologies and techniques have improved the outcomes of prostate cancer. However, it is difficult to determine the optimal RT method simply by comparing bRFS and/or morbidity rates among individual treatments. Recently, HRQOL, which is measured using questionnaires, such as the FACT-P and EPIC, has become an increasingly important end-point in the evaluation of treatments for localized prostate cancer.41,42

Maruyama et al. reported long-term results of HRQOL assessments carried out at five time points (immediately before and immediately after the initiation of CIRT, and at 12, 36 and 60 months after completion of CIRT) using the FACT-P questionnaire.43 In their study, the absolute change in the FACT-P score was minimal, and the transient decrease observed in the TOI score returned to baseline at 1 year after CIRT. Their results suggested that the changes in the HRQOL score observed after CIRT was minimal compared with the results from a previous report on photon beam RT

---

**Table 1** Clinical outcomes of photon and PBT trials carried out in the 1990s

| Author | No. patients | Period | Total dose (Gy) | Photon (Gy) | Proton (GyE) | End-point | Late toxicity |
|--------|--------------|--------|----------------|-------------|--------------|-----------|--------------|
| WPI and local RT | | | | | | | |
| Shipley14 | 393 | 1996–1999 | 79.2 | 50.4 (local) | 28.8 (local) | bRF (10 years) | 83% |
| Roach15 | 440 | 1995–1999 | 70.2 | 50.4 (WPI) + 19.8 (local) | – | – | |
| Local RT | | | | | | | |
| Zietman16 | 400 | 1991–1996 | 70.2 | 70.2 (local) | 4.0 (local) | bRF (5 years) | 82% |
| Kuban6 | 301 | 1993–1998 | 78.0 | 78.0 (local) | – | FFS (10 years) | 73% |
| Schulte17 | 911 | 1991–1996 | 74–75 | – | 74.0–75.0 (local) | bRF (5 years) | 82% |

| | | | | | | | |
| | | | | | | | |

†As the details of three patients with grade ≥3 rectal bleeding are unknown, the percentages in the table are based on the assumption that all three received high-dose RT using protons.

---

© 2019 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.
and brachytherapy (Table 4).\textsuperscript{43,44} Furthermore, a decrease in the TOI score was related to use of adjuvant ADT, onset of adverse events and biochemical recurrence.\textsuperscript{43} One likely reason why there was little effect on the HRQOL score might be the lower rates of adverse events and biochemical recurrence after CIRT.

Gray et al. compared the bowel/rectal and urinary QOL after 3DCRT (n = 123), IMRT (n = 153) and PBT (n = 95).\textsuperscript{45} During the immediate post-treatment period (2 months from the start of treatment for the IMRT cohort, and 3 months from the start of treatment for the 3DCRT and PBT cohorts), patients in the IMRT, but not the PBT, cohort reported a clinically meaningful decrease in both bowel/rectal and urinary (irritation/obstruction and incontinence) QOL. In contrast, at 12 months, patients who received PBT, but not those who received IMRT or 3DCRT, reported a clinically meaningful decrease in urinary irritation/obstruction QOL.\textsuperscript{45} At the University of Florida (USA), 1243 patients treated with 76–78 Gy PBT were compared with 204 patients treated with nearly the same dose of IMRT (75.6–79.4 Gy) in terms of HRQOL based on the EPIC score. Urinary and sexual function did not differ during the treatment course when the

### Table 2  Comparison of IMRT with particle beam therapy for treatment of prostate cancer

| Author     | Year | RT type | No. patients | Total dose (Gy/GyE) | Fractions | 5-year bRFS/bRFS (%) | Toxicity (grade 2) |
|------------|------|---------|--------------|---------------------|-----------|---------------------|-------------------|
|            |      |         |              |                     | Low-risk  | Intermediate-risk   | High-risk         |
| Zalefsky\textsuperscript{26} | 2006 | X-ray   | 561          | 81                  | 45        | 89 (8 years)†      | 78 (8 years)†     | 67 (8 years)†     | 1.6 15 |
| Kupelian\textsuperscript{26} | 2007 | X-ray   | 770          | 70                  | 28        | 94†                | 83†               | 72†               | 6 7   |
| Vora\textsuperscript{26} | 2007 | X-ray   | 145          | 70.2–77.4          | 39–43     | 88§                | 73§               | 60§               | 24 29 |
| Cahlon\textsuperscript{28} | 2008 | X-ray   | 478          | 86.4                | 48        | 98†                | 85†               | 70†               | 4 16  |
| Martin\textsuperscript{29} | 2009 | X-ray   | 92           | 79.8                | 45        | 88§                | 77§               | 78§               | 13.7 12.1 |
| Spratt\textsuperscript{30} | 2013 | X-ray   | 1002         | 86.4                | 48        | 98 (7 years)§     | 86 (7 years)§     | 68 (7 years)§     | 4.4 21.1 |
| Guckenberger\textsuperscript{31} | 2014 | X-ray   | 150          | 73.9–76.2          | 32–33     | 88§                | 80‡               | 78‡               | 4.7 22.4 |
| Lieng\textsuperscript{32} | 2017 | X-ray   | 123          | 60–66              | 20–22     | 100‡               | 89‡               | 56‡               | 7.3 12.2 |
| Takemoto\textsuperscript{33} | 2018 | X-ray   | 348          | 72.8–79            | 33–39     | 93 (7 years)‡     | 93 (7 years)‡     | 80 (7 years)‡     | 10.1 6.0 |

### Table 3  Late toxicity according to dose fractionation schedule after carbon-ion therapy

| Author     | Dose fractionation (Gy/Efr/weeks) | No. patients | Median follow-up time (months) | Rectal toxicity (%) | GU toxicity (%) |
|------------|----------------------------------|--------------|--------------------------------|---------------------|-----------------|
|            | G0     | G1     | G2     | G3     | G0     | G1     | G2     | G3     |
| Ishikawa\textsuperscript{8} | 66.0/20/5 | 250 | 43.0 | 78.0 | 18.8 | 3.2 | 0 | 40.4 | 46.0 | 13.6 | 0 |
| Ishikawa\textsuperscript{8} | 66.0/20/5 | 216 | 43.0 | 85.2 | 12.5 | 2.3 | 0 | 50.0 | 43.1 | 6.5 | 0.5 |
| Okada\textsuperscript{39} | 57.6/16/4 | 198 | 59.3 | 88.9 | 9.6 | 1.5 | 0 | 58.6 | 39.4 | 2.0 | 0 |
| Nomiya\textsuperscript{38} | 51.2/12/3 | 46 | 32.3 | 91.3 | 8.7 | 0 | 0 | 50.0 | 50.0 | 0 | 0 |

### Table 4  TOI scores after different treatments for prostate cancer

| Treatment | No. patients | Median age (years) | Baseline | 1 month | 12 months | 36 months |
|-----------|--------------|--------------------|----------|---------|-----------|-----------|
| Mean TOI score\textsuperscript{43,44} (change from baseline) | | | | | | |
| RP        | 23           | 61                 | 88.3 ± 12.3 | 66.2 ± 10.3 (−22.1) | 88.2 ± 3.7 (−0.1) | NA |
| Brachytherapy | 44        | 67                 | 86.9 ± 6.0 | 68.6 ± 7.7 (−18.3) | 85.8 ± 7.3 (−1.1) | NA |
| 3DCRT     | 23           | 69                 | 85.3 ± 9.1 | 77.6 ± 18.1 (−7.7) | 84.1 ± 13.7 (−1.2) | NA |
| CIRT      | 417          | 69                 | 81.8 ± 12.0 | 77.8 ± 12.1 (−4.0) | 80.3 ± 13.0 (−1.5) | 81.6 ± 13.7 (−0.2) |

© 2019 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.
comparisons between cohorts were controlled for age, prostate size, ADT use and baseline QOL, but the frequencies of “moderate/big problems” with rectal urgency ($P = 0.02$) and bowel frequency ($P = 0.05$) were greater in the IMRT cohort. In fact, Fang et al. assessed the associations between toxicity and PBT compared with IMRT in prostate cancer patients using a case-matched analysis; the risks of late GI and GU toxicities were not different between the two groups. However, grade $\geq 2$ acute GI toxicities were recorded in 13 (13.8%) patients treated with IMRT and four (4.3%) patients treated with PBT, and PBT was significantly associated with a reduced risk of acute GI toxicities in univariate analysis ($P = 0.03$). Based on these results, the HRQOL indicators in low- and intermediate-risk patients receiving PBT or IMRT are currently being compared (PARTIQoL trial: NCT01617161). That trial is the first to compare IMRT with PBT directly, and evaluation of the primary end-point, the EPIC mean bowel score at 24 months post-treatment, is scheduled for completion in December 2019.

To summarize these results, although no comparative study results are available at the present time, the current National Comprehensive Cancer Network guidelines on PBT state that, based on the results of many clinical studies, there is no clinical evidence supporting a benefit or disadvantage of PBT over IMRT in terms of treatment efficacy or long-term toxicities. The usefulness of PBT has been confirmed, and conventionally fractionated prostate PBT can be considered a reasonable alternative to X-ray-based regimens at clinics with the appropriate technology, physics and clinical expertise.

**Future prospects**

Particle beam RT for prostate cancer in Japan has changed considerably, and as of April 2018, it is eligible for insurance coverage. Of note, patients can receive particle beam RT without paying expensive fees, and the cost of this advanced medical treatment is similar to those of other RTs, such as IMRT and brachytherapy. The cost–benefit of particle beam RT was previously considered inferior to that of photon beam RT, but with development of this treatment modality, particle beam RT might now provide a potential cost-effective treatment in Japan. However, to establish the routine use of particle beam RT worldwide, it is still necessary to further reduce the size and cost of the device for particle beam RT.

Furthermore, recent technological advances have led to changes in the beam delivery, position verification and radiation techniques of particle beam RT, which will not only improve treatment outcomes, but also reduce the cost and treatment time. In particular, image-guided intensity-modulated particle beam RT using a new beam delivering method, known as pencil beam scanning, provides more highly conformal and precise treatments beyond what were available previously (Fig. 3). By further decreasing the irradiated volumes and doses in the rectum and bladder, the incidence of GI and GU toxicities is expected to decrease.

With an increase in the number of patients treated with particle beam RT (Fig. 4), creating a system that allows treatment of more patients while maintaining treatment quality is critical. To overcome this issue for the future, hypofractionation is a promising strategy, especially for prostate cancer treatment, based on radiobiological models. In fact, several studies of hypofractionated particle beam RT for prostate cancer have been carried out, and reported the same or lower incidences of adverse events as those seen with conventional photon beam RT using standard fractionation. Further confirmation of the feasibility and efficacy of hypofractionated particle beam RT will enable an increase in patient volume and reduction in the cost per patient. Currently, the JASTRO is carrying out a multi-institutional prospective study of hypofractionated particle beam RT, using PBT for intermediate-risk and CIRT for high-risk prostate cancer. Furthermore, another multi-institutional study of IMRT for all prostate cancer risk groups is currently being carried out. Although the outcomes obtained from these prospective studies cannot be compared directly, JASTRO intends to evaluate the efficacies of the various RT modalities for prostate cancer.

**Conclusions**

Due to a lack of direct evidence, the superiority of particle beam RT over photon beam RT for prostate cancer has not been confirmed in terms of the rates of overall survival or bRFS as end-points. However, charged particles, such as
protons and carbon ions, reduce the irradiated volumes and doses in the organs at risk surrounding the prostate, and previous studies have shown very low incidences of GI and GU toxicities after particle beam RT. Here, we reviewed treatment outcomes during different eras of particle beam RT, and the adverse events induced by particle beam RT have consistently been acceptable. Long-term observation in a large-scale randomized study is necessary for the most accurate evaluation of the efficacy of particle beam RT for prostate cancer, but particle beam RT seems a reasonable RT method delivering a high RT dose safely. During 2015–2017, the JASTRO committee for particle beam RT discussed this matter. At that time, particle beam RT was still considered an advanced medical treatment, and it was expected that patients would not refuse randomization in clinical trials. Therefore, we are carrying out a multi-institutional prospective study of IMRT, PBT and CIRT, and registration of all studies will be completed by April 2020. Together with the recent increase in the number of facilities offering particle beam RT in Japan (Table 5), data on treatment outcomes for various diseases including prostate cancer have accumulated, and are stored in a nationwide database. In addition, it is possible that the treatment devices will become smaller in size and less expensive in the near future. We are facing an important point at which particle beam RT can be compared directly with not only IMRT, but also other alternative treatments, such as surgery or brachytherapy, from several points of view, such as recurrence, adverse events, QOL and cost.

Acknowledgments

This research was supported by AMED under grant number JP18ck0106241h0003. We thank Takeji Sakae who made a figure for the pencil beam scanning method and gave us specific comments for a dose delivery system for particle therapy.

Conflict of interest

Mikio Sugimoto receives lecture fees from Janssen, Takeda and AstraZeneca. Nobuo Shinohara received research grants from Astellas and Ono, and honoraria from GlaxoSmithKline, Novartis, Pfizer, Ono, Takeda, Chugai and Bayer. Hiroki Shirato receives grants from Hitachi and Shimadzu Corporation, and has a licensed patent titled “Moving body pursuit irradiating device and positioning method using this device” and a licensed patent titled “Charged particle beam system” (US 14/524 495). Hitoshi Ishikawa, Hiroshi Tsuji, Shigeyuki
Table 5: Particle beam RT facilities in Japan

| Prefecture | City     | Institute                          | Particle        | Start of treatment (year) |
|------------|----------|------------------------------------|-----------------|---------------------------|
| Ibaraki    | Tsukuba  | University of Tsukuba              | Proton          | 1983                      |
| Chiba      | Kashiwa  | National Cancer Center Hospital East | Proton          | 1998                      |
| Hyogo      | Tatsuno  | Hyogo Ion Beam Medical Center       | Proton/carbon    | 2001                      |
| Shizuoka   | Nagaizumi| Shizuoka Cancer Center             | Proton          | 2003                      |
| Fukushima  | Koriyama | Southern Tohoku Proton Therapy Center | Proton          | 2008                      |
| Fukui      | Fukui    | Fukui Prefectural Hospital          | Proton          | 2011                      |
| Kagoshima  | Ibusuki  | Medipolis Proton Therapy and Research Center | Proton | 2011                      |
| Aichi      | Nagoya   | Nagoya City West Medical Center     | Proton          | 2013                      |
| Nagano     | Matsumoto| Aizawa Hospital University          | Proton          | 2014                      |
| Hokkaido   | Sapporo  | Hokkaido University                 | Proton          | 2014                      |
| Okayama    | Tsuyama  | Tsuyama Chuo Hospital/Okayama University | Proton         | 2016                      |
| Hokkaido   | Sapporo  | Sapporo Teshinkai Hospital          | Proton          | 2017                      |
| Hyogo      | Kobe     | Kobe Proton Center                  | Proton          | 2017                      |
| Osaka      | Osaka    | Hakuhokai Osaka Proton Therapy Clinic | Proton         | 2017                      |
| Aichi      | Toyohashi| Narita Memorial Proton Center       | Proton          | 2018                      |
| Hokkaido   | Sapporo  | Hokkaido Ohno Memorial Hospital     | Proton          | 2018                      |
| Nara       | Tenri    | Kouseikai Takai Hospital            | Proton          | 2018                      |
| Kyoto      | Kyoto    | Kyoto Prefectural University of Medicine | Proton      | 2018                      |
| Chiba      | Chiba    | National Institutes for Quantum and Radiological Science and Technology | Carbon | 1994                      |
| Gunma      | Maebashi | Gunma University                    | Carbon          | 2010                      |
| Saga       | Tosu     | SAGA Heavy Ion medical accelerator in Tosu | Carbon | 2013                      |
| Kanagawa   | Yokohama | Kanagawa Cancer Center              | Carbon          | 2015                      |
| Osaka      | Osaka    | Osaka Heavy Ion Therapy Center      | Carbon          | 2018                      |
| Under construction | Kanagawa Kamakura | Shonan Kamakura General Hospital | Proton          | 2020                      |
| Yamagata   | Yamagata | Yamagata University                 | Carbon          | 2020                      |

Murayama, Satoru Maruyama, Motohiro Murakami and Hideyuki Sakurai declare no conflict of interest.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018; 68: 7–30.

2. Cancer Information Service. Cancer Statistics in Japan. 2018. [Cited 28 Feb 2019.] Available from URL: https://ganjoho.jp/reg_stat/statistics/dl/index.html

3. Hamdy FC, Donovan JL, Lane JA et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 2016; 375: 1415–24.

4. Hou Z, Li G, Bai S. High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up. J. Cancer Res. Clin. Oncol. 2015; 141: 1063–71.

5. Zaorsky NG, Palmer JD, Hurwitz MD et al. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother. Oncol. 2015; 115: 295–300.

6. Kuban DA, Tucker SL, Dong L et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008; 70: 67–74.

7. Kanai T, Endo M, Minohara S et al. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1999; 44: 201–10.

8. Ishikawa H, Tsuji H, Kamada T et al. Carbon-ion radiation therapy for prostate cancer. Int. J. Urol. 2012; 19: 296–305.

9. Pugh TJ, Lee AK. Proton beam therapy for the treatment of prostate cancer. Cancer 2014; 20: 415–20.

10. Vargas C, Flyer A, Mahajan C et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008; 70: 744–51.

11. Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three-dimension- nal conformal radiation therapy affects the outcome in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1998; 41: 491–500.

12. Lyons JA, Kupelian PA, Mohan DS et al. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1–T3 adenocarcinoma of the prostate. Urology 2000; 55: 85–90.

13. Fowler JF, Ritter MA, Chappell RJ et al. Multi-institutional phase II study of pro- ton therapy and intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003; 56: 1093–104.

14. Shipley WU, Verhey LJ, Unznerider JE et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1995; 32: 3–12.

15. Roach M 3rd, DeSilvio M, Valicenti R et al. Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int. J. Radiat. Oncol. Biol. Phys. 2006; 66: 647–53.

16. Zietman AL, Bae K, Slater JD et al. Randomized trial comparing conven- tional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95–09. JAMA 2010; 303: 1046–53.

17. Schulte RW, Slater JD, Rossi CJ Jr et al. Value and perspectives of proton radiation therapy for limited stage prostate cancer. Strahlenther. Onkol. 2000; 176: 3–8.

18. Nihei K, Ogin T, Ishikura S et al. Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan. Jpn. J. Clin. Oncol. 2005; 35: 745–52.

19. Nihei K, Ogin T, Onozawa M et al. Multi-institutional phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. Int. J. Radiat. Oncol. Biol. Phys. 2011; 81: 390–6.

20. Akalaka K, Tsuji H, Morita S et al. Phase II/III clinical trials of carbon ion therapy for prostate cancer. Prostate 2004; 58: 252–8.

21. Ishikawa H, Tsuji H, Kamada T et al. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother. Oncol. 2006; 81: 57–64.

22. D’Amico AV, Manola J, Lucia M et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized control trial. JAMA 2004; 292: 821–7.
Particle therapy for prostate cancer

23 Roach M 3rd, Lu J, Pilepich MV et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int. J. Radiat. Oncol. Biol. Phys. 2006; 65: 1415–9.
24 Bolla M, Van Tienhoven G, Warde P et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010; 11: 1066–73.
25 Zelefsky MJ, Chan H, Hunt M et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J. Urol. 2006; 176: 1415–9.
26 Kupelian PA, Willipighb TR, Reddy CA et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int. J. Radiat. Oncol. Biol. Phys. 2007; 68: 1424–30.
27 Vora SA, Wong WW, Schild SE et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity modulated radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007; 68: 1053–8.
28 Cahlon O, Zelefsky MJ, Shippy A et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int. J. Radiat. Oncol. Biol. Phys. 2008; 71: 350–7.
29 Martin JM, Bayley A, Bratton R et al. Image guided dose escalated prostate radiotherapy: still room to improve. Radiat. Oncol. 2009; 4: 50.
30 Spratt DE, Pei X, Yamada J et al. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2013; 85: 686–92.
31 Guckenberger M, Lawrenz I, Flenje M et al. Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT. Strahlenther. Onkol. 2014; 190: 48–53.
32 Lieng H, Pinlilie M, Bayley A et al. Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. Radiother. Oncol. 2017; 122: 93–8.
33 Takamoto S, Shibamoto Y, Sugie C et al. Long-term results of intensity-modulated radiotherapy with three dose-fractionation regimens for localized prostate cancer. J. Radiat. Res. 2019; 60: 221–7.
34 Mendenhall NP, Bryant C, Hoppe BS et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2014; 88: 596–602.
35 Bryant C, Smith TL, Henderson RH et al. Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2016; 95: 422–34.
36 Takagi M, Demizu Y, Terasihima K et al. Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med. 2017; 6: 2234–43.
37 Iwata H, Ishikawa H, Takagi M et al. Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group. Cancer Med. 2018; 7: 677–89.
38 Nomiyama T, Tsuji H, Kawamura H et al. A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: a report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS). Radiatother. Oncol. 2016; 121: 288–93.
39 Okada T, Tsuji H, Kamada T et al. Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions. Int. J. Radiat. Oncol. Biol. Phys. 2012; 84: 968–72.
40 Nomiyama T, Tsuji H, Maruyama K et al. Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks. Br. J. Cancer 2014; 110: 2389–95.
41 Frank SJ, Pisters LL, Davis J 1 et al. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy implantation as monotherapies for localized prostate cancer. J. Urol. 2007; 177: 2151–6.
42 Whiting PF, Moore TH, Jameson CM et al. Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review. BJU Int. 2016; 118: 193–204.
43 Maruyama K, Tsuji H, Nomiyama T et al. Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer. J. Radiat. Res. 2017; 58: 260–6.
44 Lee WR, Hall MC, McQuellon RP et al. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51: 614–23.
45 Gray PJ, Paly JI, Yeap BY et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 2013; 119: 1729–35.
46 Hoppe BS, Michalski JM, Mendenhall NP et al. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 2014; 120: 1076–82.
47 Fang P, Mick R, Deville C et al. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer 2015; 121: 1118–27.
48 Konski A, Speier W, Hanlon A et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J. Clin. Oncol. 2007; 25: 3603–8.
49 Schroock FR, Jacobs BL, Bhayani SB. Cost of new technologies in prostate cancer treatment: systematic review of costs and cost effectiveness of robotic-assisted laparoscopic prostatectomy, intensity-modulated radiotherapy, and proton beam therapy. Eur. Urol. 2017; 72: 712–35.
50 Kase Y, Yamashita H, Fuji H et al. A treatment planning comparison of passive-scattering and intensity-modulated proton therapy for typical tumor sites. J. Radiat. Res. 2012; 53: 272–80.
51 Tran A, Zhang J, Woods K et al. Treatment planning comparison of IMPT, VMAT and IMRT for prostate cases. Radiat. Oncol. 2017; 12: 10.
52 Landry G, Hua CH. Current state and future applications of radiological image guidance for particle therapy. Med. Phys. 2018; 45: e1886–95.
53 Maeda Y, Sato Y, Minami H et al. Positioning accuracy and daily dose assessment for prostate cancer treatment using in-room CT image guidance at a proton therapy facility. Med. Phys. 2018; 45: 1832–43.
54 Nakajima K, Iwata H, Ogino H et al. Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer. Int. J. Clin. Oncol. 2018; 23: 353–60.